Recent business developments include multiple agreements for PET-CT scanner sales and rentals, capital raises to support growth, strategic partnerships, and corporate restructuring initiatives.

• Positron Corporation raised $2 million to expand market presence and growth initiatives in December 2025 [N1].
• The company entered an industry partnership agreement with MedAxiom in October 2025 [N2].
• Positron announced new corporate headquarters and strategic redomiciling to Delaware in August 2025 [N3].
• The company expanded market presence with the sale of NeuSight PET-CT scanners in May 2025 [N4].
• Positron secured agreements to sell multiple PET-CT scanners in early 2025, including four scanners in April and three 64-slice scanners in February [N5][N7].
• The company secured $8 million in capital in March 2025 to accelerate growth and market expansion [N6].
• Positron announced sales of Attrius PET and NeuSight PET-CT scanners in January 2025 [N8].

Positron Corporation benefits from the structural transition in nuclear cardiology from SPECT to PET-CT imaging, supported by clinical guidelines and reimbursement trends favoring PET. The company's cost-effective PET-CT systems, combined with flexible financing and comprehensive support services, may facilitate adoption in underserved mid-sized hospitals and outpatient centers. Strategic partnerships and capital raises provide resources to expand market presence and accelerate commercialization. The introduction of next-generation PET-CT systems with multi-disciplinary applications in oncology and neurology could broaden the addressable market. Positron's integrated approach and operational efficiencies position it to participate in the anticipated replacement cycle of legacy imaging systems.

The company has a history of operating losses and substantial accumulated deficits, with significant doubt about its ability to continue as a going concern without additional financing. Positron faces intense competition from large multinational OEMs with greater financial, technical, and marketing resources. Barriers to adoption include high capital costs, operational complexity, and dependence on third-party suppliers and radiopharmaceutical availability. Regulatory challenges and evolving reimbursement policies may impact market acceptance. The company's limited scale and resources may constrain its ability to compete effectively and achieve sustained profitability.

Positron's competitive moat is based on its specialized focus on cardiac PET and PET-CT imaging, proprietary imaging systems optimized for cardiovascular applications, and advanced cardiac-specific imaging software. The company integrates clinical and technical support services, including training, billing assistance, and 24/7 technical support, which enhances customer retention and system uptime. Flexible financing options such as rental and lease-to-own programs reduce capital barriers for customers. Strategic collaboration with Neusoft Medical Systems provides manufacturing scale and technical expertise. Positron's targeted market approach to mid-sized hospitals and outpatient centers, combined with competitive pricing near SPECT-CT systems, supports broader adoption. However, the company faces strong competition from large multinational OEMs with greater resources and established market presence.

• Operating Losses and Going Concern: Positron has sustained substantial losses with a net loss of $10.6 million in 2025 and an accumulated deficit of approximately $145 million. There is substantial doubt about the company's ability to continue as a going concern without additional financing.
• Competition: The company competes with large multinational OEMs such as GE HealthCare, Philips Healthcare, and Siemens Healthineers, which have greater resources and established market presence.
• Regulatory and Reimbursement Risks: Changes in regulatory requirements or reimbursement policies could adversely affect adoption and financial performance.
• Supplier Dependence: Positron relies on third-party suppliers and contract manufacturing, primarily through Neusoft Medical Systems, which could pose risks if disruptions occur.
• Market Acceptance and Technological Change: Adoption of PET-CT imaging faces barriers including capital costs and operational complexity. Technological advances by competitors could render products obsolete.

• Positron Corporation is a medical technology company incorporated in Texas in 1983 with headquarters in North Tonawanda, New York.
• The company develops, manufactures, and sells PET and PET-CT imaging systems focused on cardiac PET imaging with expanding presence in oncology and neurology.
• Positron's products include proprietary PET and next-generation PET-CT platforms, including the Affinity™ PET-CT 4D 64-slice system under regulatory review.
• The company collaborates with Neusoft Medical Systems subsidiary for product development, manufacturing, and distribution in North America.
• Positron offers clinical, training, technical support, and flexible financing including rental and lease-to-own programs to facilitate adoption.
• The imaging systems are primarily used for non-invasive diagnosis and management of coronary artery disease and other cardiovascular conditions.
• The company targets mid-sized hospitals, outpatient imaging centers, and physician practices, emphasizing cost-effective and operationally efficient solutions.
• Positron's systems are designed to improve diagnostic accuracy, workflow efficiency, and patient outcomes while reducing total cost of ownership.
• The company has an installed base of imaging systems and maintains long-standing relationships with cardiologists and imaging centers.
• Positron's service model includes 24/7 technical assistance, remote diagnostics, and field service engineers to maintain system uptime above 98%.
• The company faces competition from large multinational OEMs like GE HealthCare, Philips Healthcare, and Siemens Healthineers, which have greater resources.
• Positron's competitive strengths include focused cardiac PET-CT expertise, proprietary imaging systems, cardiac-specific software, integrated support, and flexible financing.
• The company is expanding its product offerings beyond cardiology into oncology and neurology with next-generation PET-CT systems.
• The U.S. nuclear cardiology market is transitioning from SPECT to PET-CT imaging, driven by clinical advantages and reimbursement dynamics.
• Positron's PET-CT systems are priced competitively, often near SPECT-CT system price points, aiming to lower barriers to adoption.
• The company has received deposits and secured agreements for multiple PET-CT scanner sales and rentals, indicating commercial traction.
• Positron has raised capital including $8 million in March 2025 and $2 million in December 2025 to support growth and market expansion.
• The company plans to pursue uplisting to a more prominent public market to enhance visibility and capital access.
• Financial snapshot as of December 31, 2025: revenue of $461,452, net loss of $10,603,392, basic and diluted EPS of -$0.34, cash and equivalents of $28,000, current assets of $3,339,186, current liabilities of $2,402,141, current ratio 1.39, cash ratio 0.01.
• The company has a history of operating losses and substantial accumulated deficit, with substantial doubt about its ability to continue as a going concern without additional financing.
• Positron's sales and marketing efforts include direct sales, participation in industry events, and targeted advertising to increase brand awareness and generate sales.
• The company provides comprehensive customer support including physician and technologist training, billing assistance, and clinical over-read support.
• Positron holds trademark registrations for Positron®, Attrius®, and Affinity PET-CT™.
• The company is undergoing regulatory testing and evaluation for its Affinity PET-CT system in collaboration with Intertek.
• The company relies on third-party suppliers and contract manufacturing, primarily through Neusoft Medical Systems, for production of imaging systems.
• Reimbursement for PET imaging is generally favorable compared to SPECT, supporting adoption in nuclear cardiology.
• The company faces risks including competition, technological change, regulatory compliance, and dependence on third-party suppliers.
• Recent business developments include multiple PET-CT scanner sales agreements, capital raises, partnership agreements, and strategic redomiciling to Delaware.